Actinium, Astellas to create actinium-225 radiotherapies

2020 07 23 21 58 4280 Cancer Radiotherapy 400

Immunotherapy technology developer Actinium Pharmaceuticals will work with Astellas Pharma to develop new actinium-225 targeted radiotherapies.

Actinium's antibody warhead-enabling platform and selected targeting agents from Astellas will be used to develop radiotherapies based on actinium-225, which has potential as a cancer-killing radioisotope.

Page 1 of 435
Next Page